Poniard Pharmaceuticals to Host Third Quarter 2008 Financial Results Conference Call on October 30

Thursday, October 23, 2008 General News J E 4
SOUTH SAN FRANCISCO, Calif., Oct. 23 PoniardPharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused ononcology, today announced that it will hold a conference call to discuss theCompany's third quarter results and provide a corporate update, including anupdate on the ongoing development activities for picoplatin, the Company'slead product candidate.

Jerry McMahon, Ph.D., chairman and chief executive officer, Ronald A.Martell, president and chief operating officer, Caroline Loewy, chieffinancial officer, and Robert De Jager, M.D., FACP, chief medical officer,will host the call beginning at 5:00 p.m. Eastern time (2:00 p.m. Pacifictime) on Thursday, October 30. A press release for the third quarter endedSeptember 30, 2008, will be released after markets close on October 30.

To participate in the live call by telephone, please dial 877-419-6593from the U.S. or 1-719-325-4885 for international callers. In addition, thelive conference call is being webcast and can be accessed on the "Events" pageof the "News & Events" section of the Company's website at A replay of the webcast will be available on theCompany's website for 10 days.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused onthe development and commercialization of innovative oncology products toimpact the lives of people with cancer. Picoplatin, the Company's leadplatform product candidate, is a new generation platinum therapy with animproved safety profile relative to existing platinum-based cancer therapies.Picoplatin is designed to overcome platinum resistance associated withchemotherapy in solid tumors, and is being studied in multiple cancerindications, combinations and formulations. Clinical trials of intravenouspicoplatin include a Phase 3 trial in small cell lung cancer and Phase 2trials in metastatic colorectal and hormone-refractory prostate cancers, aswell as a clinical trial of oral picoplatin in solid tumors. Picoplatin hasnot been approved by any regulatory authority for use in humans. Foradditional information please visit

(C) 2008 Poniard Pharmaceuticals, Inc. All Rights Reserved.

Poniard and Poniard Pharmaceuticals are trademarks of PoniardPharmaceuticals, Inc.

SOURCE Poniard Pharmaceuticals, Inc.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Winning Entry from Oncology On Canvas(SM) Art Comp...
Research Identifies New Link Between Tart Cherries...